We’d love to hear your feedback on this activity. It helps us to continually improve our products.
We had the pleasure of talking with Ailsa Bosworth, a patient advocate for rheumatoid arthritis (RA), and Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. In this interview, Ailsa explores NRAS’s profound impact on the RA community, and her role and experiences within the NRAS, and pivotal contributions to pioneering […]
We are joined by Ailsa Bosworth, Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. Ailsa Bosworth is a patient advocate for rheumatoid arthritis (RA) and joins us in this interview to discuss her personal journal to, and following, diagnosis of seronegative RA and the challenges she has faced along the […]
Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity and safety of JAK inhibitors, and how they are used to target the pathophysiology of […]
Juvenile idiopathic arthritis awareness week (JIAAW) is taking place between 3-7 July to raise awareness and dispel misconceptions around JIA, this year’s theme is #BustingJIAMyths, you can take part by entering the ‘JIA Mythbuster’ quiz and joining the conversation on social media using #BustingJIAMyths and #JIAAW2023. touchIMMUNOLOGY were delighted to talk with CEO Clare Jacklin and support […]
touchIMMUNOLOGY spoke with editorial board member Jérôme Avouac (Hôpital Cochin, Paris, France) to discuss his highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of rheumatoid arthritis, and his presentation on the potential of CD19-targeted CAR-T cell transfer for systemic sclerosis. The abstract ‘Effects of B cell depletion by […]
There is a lack of biomarkers to profile phenotypes in giant cell arteritis (GCA) and predict potential complications. Serum protein profiling may identify molecular-based phenotypes and facilitate personalized medicine approaches. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about her study which investigated the serum protein signature of clinically defined GCA […]
Giant cell arteritis (GCA) is a primary systemic vasculitis characterised by systemic inflammation and vascular insufficiency of large and medium blood vessels which may lead to end-organ damage in patients age 50 and older. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about the unmet needs in the pathogenesis of […]
In this study a machine-learning approach was investigated over two years to determine the efficacy of fracture risk prediction in osteoporosis. touchIMMUNOLOGY were delighted to speak with Dr. Giovanni Adami (University of Verona, Verona, Italy) to discuss the machine-learning models already available for screening osteoporosis and their limitations, the risk factors used as predictors of […]
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Get the latest clinical insights from touchIMMUNOLOGY